Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer

Yuliang Jiang1 | Zhe Liu1 | Feng Xu1 | Xichen Dong1 | Yurong Cheng1 |
Yizhang Hu1 | Tianbo Gao1 | Jian Liu2 | Lei Yang2 | Xingyuan Jia2 | Haili Qian3 |
Tao Wen2 | Guangyu An1

1Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2Medical research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
3Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Correspondence
Guangyu An
Email: anguangyu@hotmail.com
and
Tao Wen
Email: wentao5281@163.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81572825;
National Natural Science Foundation of China, Grant/Award Number: 81672338;
Beijing Natural Science Foundation, Grant/Award Number: 7172083

Abstract
Aberrant O-glycosylation is frequently observed in colorectal cancer (CRC) patients, but it is unclear if it contributes intrinsically to tumorigenesis. Here, we investigated the biological consequences of aberrant O-glycosylation in CRC. We first detected the expression profile of Tn antigen in a serial of human CRC tissues and then explored the genetic and biosynthetic mechanisms. Moreover, we used a human CRC cell line (LS174T), which express Tn antigen, to assess whether aberrant O-glycosylation can directly promote oncogenic properties. It showed that Tn antigen was detected in around 86% human primary and metastatic CRC tissues. Bio-functional investigations showed that T-synthase and Cosmc were both impaired in cancer tissues. A further analysis detected an occurrence of hypermethylation of Cosmc gene, which possibly caused its loss-of-function and a consequent inactive T-synthase. Transfection of LS174T cells with WT Cosmc restored mature O-glycosylation, which subsequently down-regulated cancer cell proliferation, migration and apoptotic-resistant ability. Significantly, the expression of MUC2, a heavily O-glycosylated glycoprotein that plays an essential role in intestinal function, was uniformly reduced in human CRC tissues as well as in LS174T cells. These data suggest that aberrant O-glycosylation contributes to the development of CRC through direct induction of oncogenic properties in cancer cells.

KEYWORDS
Colorectal cancer, MUC2, mucin, O-glycosylation, Tn antigen

INTRODUCTION
Colorectal cancer (CRC) is one of the most common human malignancies and the third leading cause of cancer-related death worldwide.1-3 So far, the pathogenesis of CRC is less well understood. Somatic mutations in key proto-oncogenes or tumour suppressors such as Ras, APC and P53 have been proposed to play a tumour-initiating role.4 In addition, many studies have shown that aberrant O-glycosylation of proteins and lipids, resulting in exposure of the immature truncated O-glycans such as Tn antigen,5,6 is associated with tumorigenesis and malignant transformation in many human cancers including CRC,7 pancreatic cancer,8 breast cancer,9 liver cancer10 and ovarian cancer.11

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

J Cell Mol Med. 2018;22:4875–4885. wileyonlinelibrary.com/journal/jcmm 4875
Mucin-type O-glycosylation, which is the most common post-translational modification of many membrane bound and secreted glycoproteins, occurs in the Golgi apparatus and is regulated by a series of glycosyltransferases.\textsuperscript{12} Normally, the biosynthesis of O-glycans is initiated by polypeptide α-N-acetylgalactosaminytransferases (αGalNAc-Ts), a family of enzymes which add GalNAc to Ser/Thr residues to form the Tn antigen.\textsuperscript{13} Tn antigen is the only precursor for all mucin type O-glycans.\textsuperscript{13} For further elongation, T-synthase (core 1 β1,3galactosyltransferase) is the key enzyme during the O-glycosylation process.\textsuperscript{14} Interestingly, the expression and activity of T-synthase require an endoplasmic reticulum (ER)-resident molecular chaperone named Cosmc.\textsuperscript{15-17} Knockout of either T-synthase or Cosmc in mice causes Tn expression in vivo.\textsuperscript{18-20} Besides, in gastrointestinal tract, Tn antigen can also be elongated into core 3 O-glycans by specific glycosyltransferase-C3GnT.\textsuperscript{21} Overall, T-synthase, Cosmc and C3GnT are essential for complete O-glycosylation in colonic tissues. Accordingly, aberrant O-glycosylation in colonic tissues, characterized by Tn antigen exposure, has been suggested to arise from disturbances in the expression and activity levels of T-synthase, Cosmc and/or C3GnT.\textsuperscript{17,22,25} However, it is not known whether or how aberrant O-glycosylation may contribute to the development and progression of CRC. Here, we first reported that aberrant expression of truncated O-glycans in the form of Tn antigen expression was seen in over 85% of human colorectal cancers. We then performed exome sequencing of the key genes responsible for O-glycosylation and found no mutations in O-glycosylation genes. Notably, we observed a high frequency of the hypermethylation of the Cosmc gene in CRC tissues, which may provide an explanation for the detected aberrant O-glycosylation, which we next asked whether aberrant O-glycosylation caused by Cosmc dysfunction plays a causal role for the development of CRC. We used a human CRC cell line (LS174T), which harbours islands of Cosmc and has a resultant inactive T-synthase leading to Tn expression, to demonstrate that aberrant O-glycosylation appears to directly enhance oncogenic features including altered cell growth, migration and apoptotic-resist properties in cells.

2 | MATERIAL AND METHODS

2.1 | Clinical specimens and cell line

Human primary/metastatic colorectal cancer and adjacent normal tissues were acquired from patients at Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. The study was approved by the Ethics Committees of Beijing Chao-Yang Hospital, Capital Medical University in accordance with the Declaration of Helsinki. Each patient provided a written consent. Human colorectal cancer LS174T cell line (Tn-positive) was kindly provided by Dr. Tongzhong Ju of Emory University School of Medicine in Atlanta, Georgia, USA.

2.2 | Immunohistochemical staining of Tn antigen

The formalin-fixed, paraffin-embedded tissues (n = 186) were cut into 5 μm sections. The sections were firstly stained with haematoxylin and eosin (H&E) using a standard protocol. For immunohistochemistry of Tn antigen, deparaffinized sections were boiled for 20 minutes in 0.01 mol/L citrate buffer at pH 6.0 for epitope retrieval. The sections were blocked using 0.3% H2O2 and 5% BSA. Then, sections were incubated overnight at 4°C with a specific anti-Tn IgM monoclonal antibody (5 μg/mL, CA363B, clone 12A8-C7-F5, kindly provided by Dr. Tongzhong Ju, Emory University, Atlanta, Georgia, USA)\textsuperscript{13,20,26} followed by horseradish peroxidase-conjugated antimouse IgM antibody (Abcam, ab97230) for 1 hour at room temperature. Finally, the sections were developed with DAB reagent (ZSGB-BIO, China) and counterstained with haematoxylin.

2.3 | Exome sequencing

Genomic DNA was isolated by DNA Isolation Kit (QIAGENInc.Vaclencia, CA, USA) and fragmented into 180-280 bp by sonication (Covaris). The exon enrichment library was constructed under the manufacturer’s instructions of Agilent Sure Select XT Kit (Agilent, CA, USA). The exome sequencing of 99 genes was performed by Illumina HiSeq2500 platform. Data were aligned to human genome UCSC hg19 by BWA and recalibration was performed by Picard and GATK. The Unified Genotyper module was used to detect SNP/INDEL.

2.4 | Analysis of DNA methylation by MALDI-TOF mass spectrometry

The isolated genomic DNA was bisulphate converted using EZ-96 DNA methylation kit (Zymo Research, Orange, CA, USA). CpG islands of Cosmc and T-synthase were identified through NCBI Gene Browser (http://www.ncbi.nlm.nih.gov/gene). DNA methylation primers were designed by EpiDesigner software (http://epidesigner.com). The following methylation-specific primers were used: Cosmc-Forward 5′-ATTTTTATGTTAGGGAAGGTGAAGTG3′, Cosmc-Reverse 5′-TCTTACCAAAACTATCTACAACAG3′, T-synthase-F 5′-GGTATTGTTTTTTTTTGGTGTAGT-3′, T-synthase-R 5′-TCAAAA CTTAAAACCATACAACCTTT-3′. An additional T7 promoter tag was added to each reverse primer for in vivo transcription, and a 10-mer tag was added to the forward primer to balance the PCR primer length. PCR products were treated with Shrimp alkaline phosphatase (SAP) to dephosphorylate the unincorporated dNTPs. At the same time, the RNaseA was added to cleave the transcripts (T-cleavage). The DNA methylation was quantitatively analysed by the MassARRAY platform (SEQUENOM).

2.5 | T-synthase activity assay

The assessment of the T-synthase activity was conducted using a fluorescence-based assay.\textsuperscript{27} T-synthase from the tissue lysates will form non-fluorescent Galp1-3GalNAc-α-(4-methylumbelliferone (4-MU)) by transferring Gal from UDP-Gal to GalNAc-α-(4-MU). Galp1-3GalNAc-α-(4-MU) can be cleaved by an O-glycosidase to release free 4-MU. The fluorescence intensity of 4-MU at high pH represents the activity of T-synthase. In brief, tissues extracts were
prepared using extraction buffer (25 mmol/L Tris-HCl (pH 7.4) containing 150 mmol/L NaCl and 0.5% Triton-X100). Then, a total volume of 40 μL master mixes containing 500 μmol/L GalNAc-α-4-(MU), 500 μmol/L UDP-Gal, 20 mM MnnCl2, 0.1% Triton X-100, 800 units of O-glycosidase, 50 mmol/L MES-NaOH buffer (pH 6.8) was placed in a 96-well black plate. Add 10 μL of tissue extracts to each well and incubated at 37°C for 1 hour. Then, 100 μL of 1.0 mol/L Glycine-NaOH (pH 10.0) was added to stop the reaction and the fluorescence intensity was assayed by a fluorimeter (Ex 255 nm/Em 460 nm). The fluorescence intensity of 4-MU represents the amount of T-synthase products as well as the T-synthase activity. Reaction mix without UDP-Gal was used as a control.27

2.6 RNA extraction and quantitative real-time PCR

Total RNA was extracted from frozen CRC tissues and cells using TRIzol reagent (Invitrogen, CA, USA), according to the manufacturer’s instructions. The RNA quality was assessed by a NanoDrop 2000 spectrophotometer (Wilmington, USA). Cosmc and T-synthase mRNA levels were measured by qPCR using SYBR Premix (Applied Biosystems) on the 7500 Sequence Detection System (Applied Biosystems). GAPDH was used as an internal control. The sequences of primers were as follows: COSMC forward, 5′-ACTGCAAGGCAAAAGACTCA CATCT-3′; COSMC reverse, 5′-ATGCACCACATGAGCATCATCAC 3′; T-synthase forward, 5′-TCTTACAGAAATACCTTCCGG-3′; T-synthase reverse, 5′-ATTTAACACCTCACAGCTC-3′; GAPDH forward, 5′-AATCCCATCATCCTTCCA-3′; GAPDH reverse, 5′-TGGACTCCACGACGTACTCA-3′. Relative changes in mRNA were normalized with GAPDH and calculated using 2-ΔΔCt methods.

2.7 Western blotting

Tissues or cells were lysed with RIPA lysis buffer. Total protein concentrations were measured with BCA assay kit (Thermo Fisher). Samples containing equal amount of denatured protein were separated by 10% SDS-PAGE, transferred onto PVDF membranes (Millipore) and probed with primary antibodies and horse-radish peroxidase-conjugated secondary antibodies. The detection was performed by ECL kit (Millipore) according to the manufacturer’s instruction. The following primary antibodies were used: Cosmc antibody (2 μg/mL, Santa Cruz, sc-271829), C3GnT antibody (1 μg/mL, Sigma, SAB1307144), C1GALT1 (T-synthase) antibody (2 μg/mL, Santa Cruz, sc-100745), β-actin (Cell Signaling Technology, 8457) or GAPDH (1 μg/mL, Cell Signaling Technology, 5174).

2.8 Lentiviral-mediated Cosmc transfection

The GV367-EGFP-Cosmc vector encoding Cosmc and the control vector GV367-EGFP-control were purchased from Shanghai Genechem Co. LTD (China). The Cosmc expression vector and the control were transfected into LS174T cells with polybrene (Genechem, Shanghai, China). The transfected cells were cultured for 2 days and then selected with puromycin.

2.9 Flow cytometry analysis

The cells (1 x 10^5) were resuspended in 100 μL PBS and then incubated with anti-Tn IgM mAb (20 μg/mL, CA3638, clone 12A8-C7-F5) at 4°C for 1 hour followed by incubation with PE-labelled goat antimouse IgM (Santa Cruz, sc-3768) for an hour. After washing twice with PBS, the cells were analysed by flow cytometer (BD bioscience). Similarly, for analysis of MUC2 expression, the cells were incubated with anti-MUC2 antibody (10 μg/mL, Santa Cruz, sc-15334) at 4°C for 1 hour followed by incubation with PE-labelled secondary antibody (Santa Cruz, sc-3739) and further analysed by flow cytometer (BD bioscience).

2.10 Cell proliferation, migration and apoptosis

The cell proliferation was measured by the Cell Count Kit-8 (CCK-8). The 1 x 10^4 cells were seeded into 96-well plates and incubated at 37°C. Before assay, medium was removed, 10 μL of the CCK8-solution was added to each well of the plate and incubated at 37°C for 2 hours. The optical densities (OD) were determined at 450 nm by spectrophotometer.

Cell migration was determined using wound healing assay and transwell assay. Briefly, 2 x 10^5 cells were seeded into a 6-well plate. After the cells confluence reached approximately 90%-100%, streaks were created with a pipette tip. The wells were then washed, and serum-free medium was added. The cells were observed and photographed at 24 and 48 hours after wounding. For migration assays, serum-free medium containing 2 x 10^5 cells were added into the upper chamber (BD Bioscience, 8 μm pore size). After 24 hours, the cells migrated through the pore were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet. The cells were counted and imaged under a microscope.

Apoptotic cells were examined using the PE Annexin V Apoptosis Detection Kit I (BD Biosciences). In brief, appropriate amount of cells were seeded into 35 mm tissue culture dish (Corning, 430165) with 2 mL complete medium. When the confluence reached around 80%-90%, the cells were treated with UV irradiation for 10 seconds.28,29 After 24 hours’ incubation, cells were collected and added with 5 μL of PE Annexin V and 5 μL of 7-AAD and incubated for 15 min at room temperature in the dark. Finally, 400 μL 1 x Binding Buffer was added to each tube and the occurrence of apoptotic cells was measured by flow cytometer (BD Biosciences).30

2.11 Multiplex IHC staining

Totally, 48 formalin-fixed paraffin-embedded sections of human CRC tissues were stained with Tn antigen and mucin MUC2 simultaneously performed with Opal™ 4-Color Manual IHC Kit (PerkinElmer). Briefly, the sections were first incubated with a specific anti-Tn IgM
mAb(CA3638, clone 12A8-C7-F5) for 1 hour at room temperature and then incubated with Goat antimouse IgM mu chain (HRP) (Abcam, ab97230) and eventually labelled with Opal 520 fluorophore (PerkinElmer). For the staining of MUC2, Goat anti-MUC2 antibody (2 μg/mL, Santa Cruz, sc-3739) was applied and Opal polymer HRP Ms+Rb (PerkinElmer) was subsequently added to the sections followed by incubation with Opal 690 fluorophore (PerkinElmer). Finally, all sections were counterstained with DAPI and mounted with anti-fade mountants. The inForm software (PerkinElmer) was used for analysing the multispectral images.

2.12 | Statistical analysis

All data were analysed with the SPSS 19.0 statistical software (SPSS, Chicago, IL, USA) and GraphPad Prism 6.0 (GraphPad software, La Jolla, CA, USA). All real-time PCR reactions were repeated three times. The relative quantity of the gene expression was normalized to GAPDH using 2−▵▵ct methods. The methylation level was analysed by EpiTYPE software (SEQUENOM). Continuous data were presented as the mean ± SEM and analysed with Student’s t-test. Categorical data were analysed by chi-square test. P < .05 were considered statistically significant.

3 | RESULTS

3.1 | Aberrant O-glycosylation is frequently detected in human primary and metastatic CRC

To investigate the clinical relevance of aberrant O-glycosylation, we first checked the expression of Tn antigen in archived paraffin-embedded human CRC tissues. We observed that colonic samples in 161 of the 186 (86.6%) human CRC patients were Tn positive, where all non-tumour tissues were Tn negative (Figure 1). Tn antigen was most often stained in the apical cell membranes, mucin droplet and the cytoplasm of the cancer tissues (Figure S1), suggesting a frequent occurrence of aberrant O-glycosylation. Furthermore, we analysed whether there was an association between Tn antigen expression and the clinicopathological characteristics of CRC. The results showed that Tn antigen was significantly correlated to moderate histological differentiation (P = .022) and venous invasion (P < .001) of the tumours, while it was not related to age, gender, tumour location, invasive depth, status of lymph nodes, perineural invasion and TNM stage (Table 1). Although a further large-scale systematic patient study is required, these promising data support that aberrant O-glycosylation occurs predominantly in a subset of CRC.

**FIGURE 1** Expression of aberrant O-glycans in human colorectal cancer. A, Biosynthesis of Tn antigen, and Core 1- and Core 3-derived O-glycans. Tn antigen is either modified by T-synthase and its chaperone (Cosmc) to form Core 1-derived O-glycans or processed by C3GnT to form the Core 3 structure. B, Representative H&E staining and immunohistochemical staining of Tn antigen in human primary and metastatic colorectal cancer tissues. Brown indicates positive staining for Tn antigen.
TABLE 1 Correlation of Tn antigen with clinicopathological features in patients with colorectal cancer

| Variable                  | Number of Patients | Tn expression | n   | %  | $\chi^2$ | P value |
|---------------------------|--------------------|---------------|-----|----|---------|---------|
| **Age**                   |                    |               |     |    |         |         |
| <60                       | 68                 | 58            | 85.3|    | 0.147   | .701    |
| ≥60                       | 118                | 103           | 87.2|    |         |         |
| **Gender**                |                    |               |     |    |         |         |
| Male                      | 120                | 106           | 88.3|    | 0.915   | .339    |
| Female                    | 66                 | 55            | 83.3|    |         |         |
| **Tumor location**        |                    |               |     |    |         |         |
| Colon                     | 90                 | 82            | 91.1|    | 3.11    | .078    |
| Rectum                    | 96                 | 79            | 82.2|    |         |         |
| **Histological type**     |                    |               |     |    |         |         |
| Well differentiated       | 57                 | 46            | 80.7|    | 7.60    | .022    |
| Moderate differentiated   | 92                 | 86            | 93.4|    |         |         |
| Poor differentiated       | 37                 | 29            | 78.4|    |         |         |
| **Invasive depth**        |                    |               |     |    |         |         |
| Mucose/submucosa          | 46                 | 38            | 82.6|    | 0.90    | .638    |
| Muscle layer              | 54                 | 48            | 88.9|    |         |         |
| Subserosa/serosa exposed  | 86                 | 75            | 87.2|    |         |         |
| **Lymph nodes metastasis**|                    |               |     |    |         |         |
| Absent                    | 98                 | 82            | 83.6|    | 1.48    | .223    |
| Present                   | 88                 | 79            | 89.8|    |         |         |
| **Venous invasion**       |                    |               |     |    |         |         |
| Absent                    | 58                 | 42            | 72.4|    | 14.50   | <.001   |
| Present                   | 128                | 119           | 92.9|    |         |         |
| **Perineural invasion**   |                    |               |     |    |         |         |
| Absent                    | 36                 | 29            | 80.6|    | 1.38    | .24     |
| Present                   | 150                | 132           | 88.0|    |         |         |
| **TNM Stage**             |                    |               |     |    |         |         |
| I+II                      | 88                 | 79            | 89.8|    | 1.48    | .223    |
| III+IV                    | 98                 | 82            | 83.7|    |         |         |

The chi-square test was used to analyse the associations between factors.
*P < .05 was considered to be statistically significant.

patients, and may serve as an aetiological factor for the development of CRC.

3.2 | Exploration of the mechanisms leading to Tn antigen expression in human CRC

We further investigated the mechanisms responsible for Tn antigen expression detected in patients with CRC. It is known that mature O-glycosylation depends specifically on T-synthase activity and its single chaperone-Cosmc.\(^{31}\) Besides, in colonic tissues, defective core 3 O-glycosylation could also lead to the exposure of Tn antigen.\(^{21,32}\) Here we found that the expression of C3GnT that controls core 3 O-glycosylation in cancer tissues expressing Tn antigen (Tn-positive) was comparable to that in Tn-negative cancerous tissues, thereby suggesting that there were only possible defects in T-synthase and/or Cosmc (Figure 2A). As expected, we showed that the expression and activity of T-synthase were much lower in Tn-positive CRC tissues relative to Tn-negative cancerous tissues (Figure 2A,B). Concomitantly, the expression of Cosmc, the key chaperone required for T-synthase activity and expression, was also found to be decreased in these Tn-positive cancer tissues (Figure 2A). In addition, ppGalNAc-Ts catalyze the initial O-glycosylation step,\(^{13}\) so the changes in the ppGalNAc-Ts expression may affect Tn expression. Here, we detected no significant differences in the mRNA levels of a range of ppGalNAc-Ts between Tn-positive and Tn-negative tissues (Figure S2), thus ruling out a possible involvement of ppGalNAc-Ts. Taken together, these data indicated that aberrant O-glycosylation detected in CRC tissues may result from defects in T-synthase and Cosmc.

It has been reported that somatic mutations and/or deletions in T-synthase and Cosmc may be responsible for exposure of Tn antigen.\(^{23,33,34}\) We therefore performed exome sequencing to detect if there were genetic alterations in T-synthase or Cosmc. Notably, an exome-sequence analysis of Tn-positive cancerous tissues exhibited no mutations in T-synthase, Cosmc or C3GnT, all of which are essential for mature O-glycosylation in colonic tissues (Figure S3). By contrast, a high frequency of somatic mutations was detected in TP53, APC, and K-ras, etc., which was in agreement with published literature.\(^{4}\) These findings suggest that genetic alterations in T-synthase, Cosmc and/or C3GnT are not prevailing mechanisms for such a high incidence of aberrant O-glycosylation in CRC tissues.

Recently, hypermethylation in Cosmc, which would result in Cosmc gene silencing, was reported in pancreatic tumours and Tn syndrome expressing truncated O-glycans.\(^{26,35}\) We therefore conducted a MALDI-TOF spectrometry methylation analysis of Cosmc and T-synthase in another pair of Tn-positive and Tn-negative cancer tissues. We found that hypermethylation was predominantly present in Cosmc gene in Tn-positive cancer tissues (n = 33) in contrast to Tn-negative cancer tissues (n = 32; Figure 2C,D). No hypermethylation of T-synthase gene was detected (data not shown). Our results suggested that hypermethylation of Cosmc gene may result in its loss-of-function, which consequently causes inactive T-synthase and impairs O-glycosylation process in CRC.

3.3 | Aberrant O-glycosylation enhances oncogenic properties in CRC cells

Human colorectal carcinoma LS174T cells harbour mutations in Cosmc gene and have expression of truncated O-glycans such as Tn antigen.\(^{23}\) We used LS174T cells to evaluate the biological consequence of aberrant O-glycosylation. LS174T cells were stably transfected with a plasmid encoding WT Cosmc gene. WT Cosmc transfection restored T-synthase activity and abrogated the Tn
antigen expression in these cells, indicating that the WT Cosmc could correct mature O-glycosylation (Figure 3). We then explored the biological behaviours of LS174T cells after restoration of mature O-glycosylation. The results showed that LS174T cells transfected with WT Cosmc (Tn-negative) exhibited a prominent suppression in growth and migration properties as compared with blank vector-transfected cells that still express Tn antigen (Tn-positive) (Figure 4), suggesting that lack of proper O-glycosylation enhances cancer cell proliferation and migration. In addition, we evaluated whether aberrant O-glycosylation has an influence on cell apoptosis. We treated LS174T cells with ultraviolet (UV) light to induce a significant occurrence of cell apoptosis. We found that transfection of WT Cosmc

**FIGURE 2** T-synthase and its chaperone (Cosmc) are impaired in human colorectal cancer tissues expressing Tn antigen. A, Expression of T-synthase, Cosmc and C3GnT in frozen human colorectal cancer tissues (Tn-positive = 29, Tn-negative = 22) was measured by western blotting. B, T-synthase enzymatic activity was measured in human colorectal cancer tissues (Tn-positive = 32, Tn-negative = 26). C, Analysis of Cosmc DNA methylation by MALDI-TOF mass spectrometry (Tn-positive = 33, Tn-negative = 32). D, Methylation levels of Cosmc in Tn-positive and Tn-negative cancerous tissues. ***P < .001

**FIGURE 3** Transfection of WT Cosmc in LS174T cells. A, qPCR analysis of Cosmc mRNA levels in LS174T cells transfected with WT Cosmc or blank vector. B, Western blot analysis of Cosmc expression in LS174T cells transfected with WT Cosmc or blank vector. C, FACS analysis of Tn antigen in LS174T cells transfected with WT Cosmc or blank vector. All experiments were repeated for 5 or 6 times. ***P < .001
FIGURE 4 Cosmc transfection inhibits cell proliferation and migration in LS174T cells. A, Comparison of proliferation in LS174T cells transfected with WT Cosmc or blank vector. B, Wound healing assay in LS174T cells transfected with WT Cosmc or blank vector was performed to measure cell migration. Representative photographs (left) and quantification (right) were shown. C, Transwell migration assay was performed in LS174T cells transfected with WT Cosmc or blank vector. Representative photographs (left) and quantification (right) were shown. All experiments were repeated for 5 or 6 times. ***P < .001.
remarkably increased the rate of cell apoptosis as compared to blank vector-transfected cells (Figure 5), thus suggesting that aberrant O-glycosylation endows cancer cells with significant apoptotic-resistant ability, which may favour tumour development.

3.4 | Aberrant O-glycosylation correlates with impairment of MUC2 expression

We further investigated how aberrant O-glycosylation affects cancer cell behaviours. It is known that mucins, primarily MUC2, are the predominant O-glycoproteins in the colon. MUC2 is a major component of the intestinal mucus layer and heavily modified by O-glycosylation. Altered expression of MUC2 has long been documented in patients with colorectal cancer and correlated with metastasis and prognosis. We therefore hypothesize that aberrant O-glycosylation may contribute to tumorigenesis and metastasis of cancer cells by affecting MUC2 expression and function.

In human CRC tissues, we observed that the expression of Tn antigen was inversely correlated with MUC2 expression (Figure 6A), suggesting that aberrant O-glycosylation may impair MUC2 expression. However, the decreased levels of MUC2 expression could arise from destructed epithelia as a result of severe inflammation/ulceration. It is uncertain whether MUC2 deficiency is a primary response to Tn antigen expression or secondary to inflammation. Therefore, we used LS174T cells to address whether aberrant O-glycosylation plays an aetiological role in the impairment of MUC2. A FACS analysis showed that LS174T cells containing aberrant O-glycosylation have less MUC2 expression than LS174T cells with normal O-glycosylation (Figure 6B,C), which is consistent with our clinical observation. Interestingly, we found that the mRNA levels of MUC2 were markedly increased in Tn-positive LS174T cells compared with Tn-negative cells (Figure S4), which may be due to a negative feedback regulation. These data demonstrate that mature O-glycosylation is required for the expression and/or function of its essential glycoprotein MUC2.

4 | DISCUSSION

Expression of aberrant forms of O-glycans such as Tn antigen has been frequently observed in patients with CRC and reported to be associated with tumour metastatic potential and poor prognosis. However, whether defective O-glycosylation occurs as a result of tumorigenesis or plays a contributing role in tumour development is unclear. In this study, we found that Tn antigen was frequently (over 85%) expressed in a series of clinical specimens of colorectal cancers, suggesting an involvement of aberrant O-glycosylation in CRC. More importantly, we found that hypermethylation rather than somatic mutations in Cosmc was a major cause for expression of the Tn antigen. Cosmc is required for accurate folding of T-synthase in ER. Our results were comparable with a recent report that Cosmc hypermethylation was a prevalent mechanism for aberrant expression of immature truncated O-glycans in pancreatic cancers. However, other mechanisms such as Golgi to ER relocation of the enzymes initiating O-glycosylation and altered expression of enzymes responsible for sialylation cannot be excluded and may play distinctive roles under different circumstances, which await further exploration.

So far the key question that remains unsolved is whether the expression of truncated O-glycans in cancer intrinsically has biological functions for the malignant process. The major challenge is how to find the real counterparts, for example Tn-positive versus Tn-negative tumour cells. It has been reported that human colorectal carcinoma cell line (LS174T) is a mixture of Tn-positive and Tn-negative cells. Studies have shown that Tn-positive LS174T cells have inactive T-synthase activity, which are caused by alterations in Cosmc, and transfection of WT Cosmc can restore T-synthase activity and repair O-glycosylation. Therefore, this cell model is most ideal to study how the O-glycosylation in tumour cells alters their behaviours. Our results clearly showed that Tn-positive cancer cells have significantly enhanced growth and invasion ability in contrast to Tn-negative cells. Moreover, we demonstrated that Tn-positive cells are
...more resistant to UV-induced apoptosis than Tn-negative cells. Our findings provided direct evidence that aberrant O-glycosylation plays a contributory role in the induction of oncogenic features in colorectal cancer. However, it should be noted that there are some contradictory reports regarding the biological role of aberrant O-glycosylation in a few malignancies. For example, Gao et al reported that loss of intestinal O-glycans significantly promotes spontaneous duodenal tumours in mice and aberrant O-glycosylation may serve as critical determinants of duodenal cancer risks; however, Bergstrom et al unexpectedly found that, although mice deficient in intestinal O-glycans developed typical colonic cancers, it was indeed dependent on colitis rather than aberrant O-glycosylation. In addition, several studies showed that direct deletion of Cosmc in pancreatic cancer cell lines induces classical oncogenic features, which is also in agreement with our findings. But Huang et al reported that forced overexpression of Cosmc in human colorectal cancer cell lines significantly increases malignant behaviours, whereas knockdown of Cosmc suppresses oncogenic features. Although it is unclear how these discrepancies occur, it has been unanimously accepted that altered O-glycosylation is closely associated with malignant phenotypes. The functional role of aberrant O-glycosylation in CRC remains to be further elucidated. Our study adds a new dimension to this theme by demonstrating that Cosmc dysfunction in colonic cancer is sufficient to induce aberrant O-glycosylation and consequently promotes oncogenic features, thereby supporting that aberrant O-glycosylation contributes to the progression of CRC.

Having demonstrated that aberrant O-glycosylation is a contributing factor in the development and progression of CRC, we next asked how aberrant O-glycosylation alters cancer cell behaviours. Theoretically, aberrant O-glycosylation may produce global effects on post-
translational modification of many proteins and lipids, and subsequently alters their functions involved with oncogenic properties.\textsuperscript{33} Of these O-glycosylated proteins, the secretory mucin MUC2 is stored in bulky apical granules of the goblet cells and is a most important factor maintaining intestinal homeostasis.\textsuperscript{38} As the predominant O-glycoprotein, MUC2 is heavily modified by O-glycosylation and is generally considered to be essential for epithelial protection. MUC2-lacking mice spontaneously developed colitis and colorectal cancer.\textsuperscript{53} Therefore, we assume that defective O-glycosylation may affect the expression and/or function of MUC2 that is required for suppressing intestinal cancer. Our results showed that MUC2 expression was much reduced in Tn-positive human colonic cancer tissues relative to normal tissues, suggesting that MUC2 may require mature O-glycosylation for its proper expression and stability. However, the alterations in MUC2 may also be due to the loss of epithelia as a result of severe inflammation-ulceration. To specifically address this issue, we compared the production of MUC2 in LS174T cells and found that the expression of MUC2 was substantially reduced in Tn-positive cells than in Tn-negative cells, which supports our clinical observation that aberrant O-glycosylation directly impaired MUC2 expression. Nevertheless, it should be noted that defective O-glycosylation may cause more profound effects than dysfunction of an individual O-glycoprotein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2. More efforts are needed to decipher which key pathways or glycoproteins are most often affected by truncation of protein such as MUC2.

In summary, we provide evidence for a causal role of aberrant O-glycosylation in the development of CRC, which is probably caused by hypermethylation of Cosmc, the key chaperone for T-synthase activity. Aberrant O-glycosylation may alter oncogenic behaviours in colorectal carcinomas by impairing the expression or stability of intestinal mucins, primarily MUC2. The molecular mechanisms deserved further investigation.

ACKNOWLEDGEMENT

This work was supported by National Natural Science Foundation of China (81572825 to Guangyu An, 81672338 to Tao Wen) and Beijing Natural Science Foundation (7172083 to Guangyu An).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ORCID

Tao Wen http://orcid.org/0000-0003-0675-0163

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
2. Siegel RL, Miller KD, Fedewa SA. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177-193.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132.
4. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA. 2002;99:9433-9438.
5. Springer GF, Taylor CR, Howard DR, et al. Tn, a carcinoma-associated antigen, reacts with anti-Tn of normal human sera. Cancer. 1985;55:561-569.
6. Hirohashi S, Clausen H, Yamada T, Shimosato Y, Hakomori S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc Natl Acad Sci USA. 1985;82:7039-7043.
7. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989;49:197-204.
8. Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology. 1991;100:1691-1700.
9. Springer GF, Desai PR, Banatvala I. Blood group MN specific substances and precursors in normal and malignant human breast tissues. Naturwissenschaften. 1974;61:457-458.
10. Sasaki M, Yamato T, Nakanuma Y. Expression of sialyl-Tn, Tn antigens in primary liver cancer. Pathol Int. 1999;49:325-331.
11. Ghazizadeh M, Ogawa H, Sasaki Y, Araki T, Aihara K, Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: Relationship with histopathology and prognosis. Hum Pathol. 1997;28:960-966.
12. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540-555.
13. Ju TZ, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Edit. 2011;50:1770-1791.
14. Ju TZ, Brewer K, D'Souza A, Cummings RD, Canfield WM. Cloning and expression of human core 1 beta 3 galactosyltransferase. J Biol Chem. 2002;277:178-186.
15. Ayal RP, Ju TZ, Cummings RD. The endoplasmic reticulum chaperone cosmc directly promotes in vitro folding of T-synthase. J Biol Chem. 2010;285:2456-2462.
16. Ju TZ, Longeras R, Cummings RD. Subcellular localization of human cosmc and T-synthase. Glycobioiology. 2003;13:861-862.
17. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA. 2002;99:16613-16618.
18. Xia LJ, McEver RP. Targeted disruption of the gene encoding core 1 beta 1,3-galactosyltransferase (core 1,3GlcNAc:GalNAc-peptide beta 1,3-N-acetylgalosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. J Biol Chem. 2002;277:12802-12809.
19. Wang YC, Ju TZ, Ding XK, et al. Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci USA. 2010;107:9228-9233.
20. Kudelka MR, Hinrichs BH, Darby T, et al. Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates gut microbiota and contributes to sex-specific risk. Proc Natl Acad Sci USA. 2016;113:14787-14792.
21. Iwai T, Inaba N, Naudorf A, et al. Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylgalosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. J Biol Chem. 2002;277:12802-12809.
22. Wang YC, Ju TZ, Ding XK, et al. Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci USA. 2010;107:9228-9233.
23. Ju T, Lanneau GS, Gautam T, et al. Human tumor antigens Tn and sia-lyl Tn arise from mutations in Cosmc. Cancer Res. 2008;68:1636-1646.
24. Bergstrom K, Liu XW, Zhao YM, et al. Defective intestinal Mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice. Gastroenterology. 2016;151:152-164.
25. Iwai T, Kudo T, Kawamoto R, et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA. 2005;102:4572-4577.

26. Mi R, Song L, Wang Y, et al. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. J Biol Chem. 2012;287:41523-41533.

27. Ju TZ, Xia BY, Aryan RP, et al. A novel fluorescent assay for T-synthase activity. Glycobiology. 2011;21:352-362.

28. Hussain I, Fathallah I, Accardi R, et al. NF‐kappaB protects human papillomavirus type 38 E6/E7‐immortalized human keratinocytes against tumor necrosis factor alpha and UV‐mediated apoptosis. J Virol. 2011;85:9013-9022.

29. Piva TJ, Davern CM, Hall PM, Winterford CM, Ellem KA. Increased activity of cell surface peptidases in HeLa cells undergoing UV‐induced apoptosis is not mediated by caspase 3. Int J Mol Sci. 2012;13:2650-2675.

30. Verme I, Haanen C, Steffens‐Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1999;219:39-51.

31. Ju TZ, Aryan RP, Kudelka MR, Wang Y, Cummings RD. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 2014;14:63-81.

32. An G, Wei B, Xia B, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3‐derived O‐glycans. J Exp Med. 2007;204:1417-1429.

33. Schietinger A, Philip M, Yoshida BA, et al. A mutant chaperone converts a wild‐type protein into a tumor‐specific antigen. Science. 2006;314:304-308.

34. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005;437:1252.

35. Radakrishnan P, Dabelsteen S, Madsen FB, et al. Immature truncated O‐glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci USA. 2014;111:E4066-E4075.

36. Kufe DW. Mucins in cancer: function, prognosis and therapy. Proc Natl Acad Sci USA. 2013;110:E3161-3169.

37. Kawashima H. Roles of the gel forming MUC2 mucin and its O‐glycosylation in the protection against colitis and colorectal cancer. Biol Pharm Bull. 2012;35:1637-1641.

38. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host‐microbial interactions. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4659-4665.

39. Szajda SD, Jankowska A, Zwierz K. Carbohydrate markers in colon carcinoma. Dis Markers. 2008;25:233-242.

40. Hsu HP, Lai MD, Lee JC, et al. Mucin 2 silencing promotes colon cancer metastasis through interleukin‐6 signaling. Sci Rep. 2017;7:5823.

41. Bergstrom KS, Kissoon-Singh V, Gibson DL, et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 2010;6: e1000902.

42. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-129.

43. Omrtof TF, Harving N, Langkilde NC. O‐linked mucin‐type glycoproteins in normal and malignant colon mucosa: lack of T‐antigen expression and accumulation of Tn and sialosyl‐Tn antigens in carcinomas. Int J Cancer. 1990;45:666-672.

44. Konno A, Hoshino Y, Terashima S, Motoki R, Kawaguchi T. Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clin Exp Metastasis. 2002;19:61-70.

45. Schumacher U, Higgs D, Loizidou M, Pickering R, Leathem A, Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer. 1994;74:3104-3107.

46. Gill DJ, Chia J, Senewiratne J, Bard F. Regulation of O‐glycosylation through Golgi‐to‐ER relocation of initiation enzymes. J Cell Biol. 2010;189:843-858.

47. Gill DJ, Tham KM, Chia J, et al. Initiation of GalNAc‐type O‐glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc Natl Acad Sci USA. 2013;110:E3152-E3161.

48. Marcos NT, Bennett EP, Gomes J, et al. ST6GalNAc‐I controls expression of sialyl‐Tn antigen in gastrointestinal tissues. Front Biosci. 2011;16:1443-1455.

49. Gao N, Bergstrom K, Fu J, Xie B, Chen W, Xia L. Loss of intestinal O‐glycans promotes spontaneous duodenal tumors. Am J Physiol Gastrointest Liver Physiol. 2016;311:G74-G83.

50. Bergstrom K, Liu X, Zhao Y, et al. Defective intestinal Mucin‐Type O‐Glycosylation causes spontaneous colitis‐associated cancer in mice. Gastroenterology. 2016;151(152-64):e11.

51. Hofmann BT, Schuler L, Lange P, et al. COSMC knockdown mediates aberrant O‐glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 2015;14:109.

52. Huang J, Che MI, Lin NY, et al. The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK. Mol Carcinog. 2014;53(Suppl 1):E62-E71.

53. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295:1726-1729.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Jiang Y, Liu Z, Xu F, et al. Aberrant O‐glycosylation contributes to tumorigenesis in human colorectal cancer. J Cell Mol Med. 2018;22:4875–4885. https://doi.org/10.1111/jcmm.13752